Multiple Myeloma
- 28 February 2009
- journal article
- review article
- Published by Elsevier in Current Problems in Cancer
- Vol. 33 (1), 7-64
- https://doi.org/10.1016/j.currproblcancer.2009.01.001
Abstract
No abstract availableThis publication has 152 references indexed in Scilit:
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003
- Thalidomide in the Treatment of Relapsed Multiple MyelomaMayo Clinic Proceedings, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- The Return of ThalidomideDrug Safety, 1999
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Degradation Process of Ligand-stimulated Platelet-derived Growth Factor β -Receptor Involves Ubiquitin-Proteasome Proteolytic PathwayPublished by Elsevier ,1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimensJAMA, 1969
- Méthode permettant l'étude conjuguée des propriétés électrophorétiques et immunochimiques d'un mélange de protéines. Application au sérum sanguinBiochimica et Biophysica Acta, 1953